JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/16.01.26 | Market Closed - Börse Stuttgart 10:29:18 01/07/2024 BST | ||
| 0.21 EUR | +5.00% |
|
| Current month | +5.00% | ||
| 1 month | +10.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.21 | +5.00% |
| 28/06/24 | 0.2 | -13.04% |
| 27/06/24 | 0.23 | +4.55% |
| 25/06/24 | 0.22 | 0.00% |
| 24/06/24 | 0.22 | +10.00% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 10:29 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK498C |
| ISIN | DE000JK498C0 |
| Date issued | 01/03/2024 |
| Strike | 55 $ |
| Maturity | 16/01/2026 (564 Days) |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.71 € |
|---|---|
| Lowest since issue | 0.18 € |
| Spread | 0.02 € |
| Spread % | 9.09% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.3
USD
Average target price
53.19
USD
Spread / Average Target
+28.80%
- Stock Market
- Warrants
- Warrant
